November 5, 2019 07:32 AM ESTUpdated 10:38 AM

Unum drops another program for troubled PhI therapy, moving its eggs to the solid tumor basket

Amber Tong

Senior Editor

Several months after Unum Therapeutics ran into a second safety crisis surrounding its premier Phase I therapy, the biotech is putting another ACTR087 trial to bed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Unum drops another program for troubled PhI therapy, moving its eggs to the solid tumor basket

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

The next generation of AI biotechs is here. Can they deliver on the hype?

UCB makes major management changes; Bristol Myers’ ADC partner tops list of new CEOs

Updated: FDA approves Pfizer’s hemophilia B gene therapy, with $3.5M price tag

AbbVie beats first-quarter expectations, but Humira guidance leaves analysts confused

Ophthalmic biotech raises $16.5M; Pfizer’s AI collaboration bears fruit

Gilead leans on CymaBay liver drug, Trodelvy readouts and long-active PrEP yet to come this year

Unum drops an­oth­er pro­gram for trou­bled PhI ther­a­py, mov­ing its eggs to the sol­id tu­mor bas­ket

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

more like this

The next gen­er­a­tion of AI biotechs is here. Can they de­liv­er on the hype?

UCB makes ma­jor man­age­ment changes; Bris­tol My­ers’ ADC part­ner tops list of new CEOs

Up­dat­ed: FDA ap­proves Pfiz­er’s he­mo­phil­ia B gene ther­a­py, with $3.5M price tag

Ab­b­Vie beats first-quar­ter ex­pec­ta­tions, but Hu­mi­ra guid­ance leaves an­a­lysts con­fused

Oph­thalmic biotech rais­es $16.5M; Pfiz­er’s AI col­lab­o­ra­tion bears fruit

Gilead leans on CymaBay liv­er drug, Trodelvy read­outs and long-ac­tive PrEP yet to come this year

Unum drops another program for troubled PhI therapy, moving its eggs to the solid tumor basket

The next generation of AI biotechs is here. Can they deliver on the hype?

UCB makes major management changes; Bristol Myers’ ADC partner tops list of new CEOs

Updated: FDA approves Pfizer’s hemophilia B gene therapy, with $3.5M price tag

AbbVie beats first-quarter expectations, but Humira guidance leaves analysts confused

Ophthalmic biotech raises $16.5M; Pfizer’s AI collaboration bears fruit

Gilead leans on CymaBay liver drug, Trodelvy readouts and long-active PrEP yet to come this year